Positron emission tomography (PET) has become an invaluable tool for drug discovery and diagnosis. The positron-emitting radionuclide fluorine-18 is frequently used in PET radiopharmaceuticals due to its advantageous characteristics; hence, methods streamlining access to ¹⁸F-labelled radiotracers can make a direct impact in medicine. For many years, access to ¹⁸F-labelled radiotracers was limited by the paucity of methodologies available, and the poor diversity of precursors amenable to ¹⁸F-incorporation. During the last two decades, ¹⁸F-radiochemistry has progressed at a fast pace with the appearance of numerous methodologies for late-stage ¹⁸F-incorporation onto complex molecules from a range of readily available precursors including those that do not require pre-functionalisation. Key to these advances is the inclusion of new activation modes to facilitate ¹⁸F-incorporation. Specifically, new advances in late-stage ¹⁹F-fluorination under transition metal catalysis, photoredox catalysis, and organocatalysis combined with the availability of novel ¹⁸F-labelled fluorination reagents have enabled the invention of novel processes for ¹⁸F-incorporation onto complex (bio)molecules. This review describes these major breakthroughs with a focus on methodologies for C-¹⁸F bond formation. This reinvigorated interest in ¹⁸F-radiochemistry that we have witnessed in recent years has made a direct impact on ¹⁹F-chemistry with many laboratories refocusing their efforts on the development of methods using nucleophilic fluoride instead of fluorination reagents derived from molecular fluorine gas.
No takes yet. Share an insight, caveat, or question.
Ajenjo et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: